Gastric cancer cells with Stathmin1 and microRNA-223, symbolizing targeted therapy.

Stathmin1: The Unexpected Key to Unlocking Gastric Cancer Treatment

Rhea Morgan monogram
Rhea Morgan in Health & Wellness October 2026 • 4 min read.

"Discover how a tiny protein and a microRNA could revolutionize how we understand and treat gastric cancer."


Gastric cancer remains one of the most prevalent and deadly forms of cancer globally, particularly impacting regions like China, Japan, and Korea. Despite advancements in medical science, the overall prognosis for gastric cancer patients remains poor, with survival rates often falling below 30%. Understanding the underlying mechanisms that drive gastric cancer development is crucial for devising more effective treatments and improving patient outcomes.

Recent research has shed light on the potential role of Stathmin1 (STMN1), a protein known for its involvement in cell growth and division, in the progression of gastric cancer. STMN1, also called oncoprotein 18, plays a critical role in mitosis by managing microtubule dynamics and is implicated in various other biological processes. Studies indicate that high levels of STMN1 expression are often associated with poor prognosis in several types of malignancies.

A groundbreaking study published in PLOS ONE explores the oncogenic role of STMN1 in gastric cancer and investigates its regulation by microRNA-223 (miR-223). The findings suggest that STMN1 could serve as both a prognostic marker and a potential therapeutic target for this deadly disease. Let's delve into the details of this research and understand its implications.

AI Search Multiple angles on this topic

Measuring Gastric Cancer’s Burden

Current stomach cancer reporting draws on sources such as the SEER Cancer Stat Facts database, which organizes statistics by sex, race, calendar year, age, stage, and histology. The American Cancer Society publishes recent key statistics for stomach, or gastric, cancer in the United States. The CDC explains that cancer data are used to track rates and trends, support research, measure progress in prevention and control, address disparities, and improve outcomes. Worldmetrics also reports a 2026 gastric cancer statistics report covering market data and recent research.

A Complex Treatment Landscape

Gastric cancer care generally requires decisions tailored to disease extent, tumor characteristics, and patient circumstances. Accepted approaches may combine established clinical treatments, but their benefits and limitations can vary across patients. Because no source material was provided for this subsection, these points should be treated as general context rather than a source-specific account.

An Evolving Field

The understanding and treatment of gastric cancer have developed gradually through advances in diagnosis, pathology, surgery, systemic therapy, and molecular research. Foundational discoveries have helped shift the field from broadly defined disease categories toward more biologically informed approaches. Without subsection-specific sources, this overview remains intentionally general and does not assign particular milestones or dates.

What is Stathmin1 and Why Does It Matter in Gastric Cancer?

Gastric cancer cells with Stathmin1 and microRNA-223, symbolizing targeted therapy.

Stathmin1 (STMN1) is a protein that regulates the stability of microtubules, which are crucial components of the cell's structural framework. In cancer cells, STMN1 is often overexpressed, leading to uncontrolled cell proliferation, invasion, and metastasis. The study by Kang et al. aimed to analyze STMN1 expression and its biological functions in gastric cancer, as well as to explore how microRNA-223 (miR-223) regulates it.

The research employed a combination of techniques to evaluate STMN1's role:

  • qRT-PCR: To measure STMN1 mRNA levels.
  • Western Blot: To assess STMN1 protein expression.
  • Immunohistochemistry: To visualize STMN1 protein in tissue samples.
  • MTT Proliferation Assays, Monolayer Colony Formation, and Cell Invasion Assays: To determine the functional effects of STMN1 using small interfering RNA (siRNA) in gastric cancer cell lines.
AI Search Multiple angles on this topic

Research Around STMN1

Recent investigation of gastric cancer includes interest in molecular markers such as Stathmin1, also known as STMN1. Research in this area examines whether altered protein expression may help explain tumor behavior or identify clinically useful targets. Because no sources were supplied for this subsection, these statements are broad context rather than claims about a specific study or review.

Evidence and Unresolved Challenges

Gastric cancer remains a major unmet clinical problem: a comprehensive review reported more than 1 million new cases worldwide in 2018 and described it as the fourth most commonly occurring cancer in men and the seventh in women. In diffuse-type gastric cancer, one study reported that Stathmin1 expression was positively associated with lymph-node metastasis, TNM stage, and vascular invasion, while recurrence-free survival was shorter among patients with positive expression: 7.0 months versus 17.0 months for negative expression. These findings are prognostic associations, not proof that Stathmin1-directed treatment improves outcomes. Broader treatment reviews also identify late diagnosis, treatment resistance, and side effects as continuing challenges despite advances in targeted therapy, immunotherapy, and precision medicine.

Comparing Emerging Strategies

Comparisons between conventional gastric cancer treatment and molecularly guided strategies should account for differences in tumor biology, disease stage, and patient response. A marker such as Stathmin1 may offer a way to study prognosis or treatment selection, but its clinical value cannot be assumed from laboratory or observational findings alone. No subsection-specific sources were provided, so this comparison is deliberately general and avoids unsupported rankings or numerical claims.

The study revealed several critical findings:

A Promising Future for Gastric Cancer Treatment

This research provides a compelling case for STMN1 as a potential prognostic marker and therapeutic target in gastric cancer. The discovery that miR-223 can regulate STMN1 expression opens new avenues for developing targeted therapies that could improve patient outcomes. Further studies are needed to fully elucidate the mechanisms involved and to translate these findings into clinical applications, but the future looks promising. With ongoing research and innovation, we can strive towards more effective treatments and improved survival rates for individuals affected by this devastating disease.

AI Search Multiple angles on this topic

STMN1 as a Potential Oncogenic Target

The cited gastric cancer study describes Stathmin1, or STMN1, as a candidate oncoprotein and prognosis marker and evaluates its expression using qRT-PCR, western blotting, and immunohistochemistry. It also investigates biological function through MTT proliferation assays, monolayer colony formation, and cell invasion experiments. The study’s focus on microRNA regulation supports interest in whether STMN1 could be biologically actionable, but these findings should not be presented as proof of an established therapy. A separate clinical-significance report emphasizes that prognosis for advanced gastric cancer remains poor, with 5-year survival below 30% in the majority of countries according to its cited introduction.

From Marker to Treatment

Future research may clarify whether Stathmin1 can move from a promising biomarker to a clinically useful treatment target. Important questions include whether its measurement reliably guides prognosis, whether microRNA-based regulation can be therapeutically manipulated, and whether targeting STMN1 improves patient outcomes. These possibilities remain investigational because no source material was provided for this subsection.

Age, Biology, and Resistance

A 2021 review reports that gastric cancer prevalence increases after age 40 and peaks in the seventh decade of life. The same review describes tau and stathmin as overexpressed in gastric cancer and links them with increased cancer-cell proliferation, invasion, and drug resistance. This places Stathmin1 within a broader biological and clinical context in which tumor progression and resistance may be interconnected.

Potential Patient Relevance

Research on Stathmin1 is intended to connect molecular findings with clinically meaningful questions about gastric cancer progression, prognosis, and treatment. The cited study evaluates STMN1 expression and biological effects using laboratory assays, including proliferation, colony formation, and invasion measures. Such work may eventually help distinguish patients with different risks or therapeutic needs, but the supplied source material does not establish a routine patient-care application. Its practical significance therefore remains a subject for further clinical validation.

What cell experiments can establish about STMN1

In vitro (cell or tissue) study (level 6 of 8)

The study combines laboratory experiments in gastric cancer cell lines with tissue observations, so it can show how STMN1 behaved in those settings but cannot establish that changing it benefits patients. The tissue-expression analysis covered 111 primary gastric adenocarcinoma samples; that sample count does not make the experimental findings a clinical treatment test.[1] [2]

STMN1 knockdown compared with control cells

  • 65.9% and 42.7%After STMN1 knockdown, migrating cells measured 65.9% of scramble-control levels in AGS cells and 42.7% in MKN7 cells; the reported difference was statistically significant.[1]Caveat: p<0.001

What limits the interpretation

  • The mouse experiment used injected cells and compared flank tumors after three weeks; this setup does not establish effects in human disease.[1] [2]
  • Results from sarcoma and lung cancer models offer biological context, but they are not direct evidence about gastric cancer outcomes.[1]

STMN1 knockdown and miR-223 regulation in gastric cancer

Study designIn vitro (cell or tissue) study[2]
Sample size111 primary gastric adenocarcinoma samples[2]
Duration3 weeks after injection[2]
ComparisonScramble siRNA controls[2]
Times cited92[2]

How later work places the STMN1 findings

A later review summarized the original gastric-cell experiments as showing reduced proliferation, colony formation, invasion, and migration after stathmin reduction, with cells arrested in G1 phase; this is a secondary account of laboratory evidence, not a patient-treatment result.[2] [3]

What follow-up evidence would resolve

  • Would STMN1 measurements predict disease-specific outcomes consistently across gastric cancer subtypes, given the reported survival association in diffuse-type disease and the lack of significant clinicopathological correlations in another overall cohort?[2] [4]
  • Can STMN1 suppression produce comparable effects across gastric cancer cell types, including poorly differentiated lines, and in models that better reflect human disease?[1] [2]
  • How does miR-223’s ability to target STMN1 relate to its distinct effects on cell motility, and what determines whether those effects occur together?[1]

Terms used in the study

G1 phase arrest
A cell-cycle effect reported after STMN1 knockdown in gastric cancer cell lines.[2]
Cleaved PARP
A protein signal used in the study to represent late apoptosis in gastric cancer cell lines.[1]

Sources

  1. Stathmin1 Plays Oncogenic Role and Is a Target of MicroRNA-223 in Gastric Cancer (Europe PMC, 2012)
  2. Stathmin1 Plays Oncogenic Role and Is a Target of MicroRNA-223 in Gastric Cancer (Public Library of Science (PLoS), 2012)
  3. Stathmin-dependent molecular targeting therapy for malignant tumor: the latest 5 years’ discoveries and developments (2016)
  4. High STMN1 level is associated with chemo-resistance and poor prognosis in gastric cancer patients (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.1371/journal.pone.0033919, Alternate LINK

Title: Stathmin1 Plays Oncogenic Role And Is A Target Of Microrna-223 In Gastric Cancer

Subject: Multidisciplinary

Journal: PLoS ONE

Publisher: Public Library of Science (PLoS)

Authors: Wei Kang, Joanna H. M. Tong, Anthony W. H. Chan, Raymond W. M. Lung, Shuk Ling Chau, Queenie W. L. Wong, Nathalie Wong, Jun Yu, Alfred S. L. Cheng, Ka Fai To

Published: 2012-03-28

Everything You Need To Know

1

What is Stathmin1 (STMN1) and what role does it play in the context of gastric cancer?

Stathmin1, also known as oncoprotein 18, is a protein that regulates microtubule stability within cells. Microtubules are essential for cell structure and division. In gastric cancer, Stathmin1 is often overexpressed, leading to uncontrolled cell proliferation, invasion, and metastasis. Understanding Stathmin1's role is crucial as it emerges as a potential prognostic marker and therapeutic target. Further research aims to explore Stathmin1's interaction with other molecules and its impact on overall patient survival rates.

2

How does microRNA-223 (miR-223) relate to Stathmin1 in gastric cancer, and why is this connection significant?

MicroRNA-223 (miR-223) can regulate Stathmin1 expression. This regulation is significant because by controlling Stathmin1 levels, miR-223 can potentially modulate the growth and spread of gastric cancer cells. The discovery of this regulatory mechanism opens new avenues for developing targeted therapies. If miR-223 can effectively suppress Stathmin1, it could lead to more effective treatments and improved outcomes for patients with gastric cancer. However, the precise mechanisms of this regulation still require further investigation.

3

The research mentions several techniques like qRT-PCR, Western blot, and immunohistochemistry. How are these methods used to understand Stathmin1's role in gastric cancer?

These techniques are employed to comprehensively analyze Stathmin1's involvement in gastric cancer. qRT-PCR measures Stathmin1 mRNA levels, indicating how much of the protein is being produced. Western blot assesses the actual Stathmin1 protein expression, confirming the mRNA findings. Immunohistochemistry visualizes Stathmin1 protein in tissue samples, showing its location and distribution within the tumor. MTT proliferation assays, monolayer colony formation, and cell invasion assays using small interfering RNA (siRNA) determine how Stathmin1 affects cancer cell growth and spread. By combining these methods, researchers gain a detailed understanding of Stathmin1's function and its impact on cancer progression.

4

What makes Stathmin1 a promising therapeutic target for gastric cancer, and what are the potential implications of targeting it?

Stathmin1 is a promising therapeutic target because its overexpression is associated with poor prognosis and increased cancer aggressiveness. Targeting Stathmin1 could potentially slow down or stop the growth and spread of gastric cancer cells. The implications of targeting Stathmin1 include the development of new drugs or therapies that specifically inhibit its function. This could lead to more effective treatments with fewer side effects compared to traditional chemotherapy. However, it's essential to consider potential off-target effects and ensure that inhibiting Stathmin1 doesn't harm healthy cells. Further clinical trials are needed to validate the safety and efficacy of Stathmin1-targeted therapies.

5

Given that gastric cancer prognosis remains poor, particularly in regions like China, Japan, and Korea, how could findings about Stathmin1 and microRNA-223 influence future treatment strategies and improve patient outcomes?

The findings regarding Stathmin1 and microRNA-223 offer a pathway for developing more targeted and effective treatment strategies. By identifying Stathmin1 as a prognostic marker, doctors can better assess the severity of the cancer and tailor treatments accordingly. Furthermore, understanding the regulatory role of microRNA-223 opens doors for therapies that modulate Stathmin1 expression. This could lead to personalized treatment plans that address the specific molecular characteristics of each patient's cancer. Ultimately, the goal is to improve survival rates and quality of life for individuals affected by gastric cancer, particularly in high-risk regions. However, translating these findings into clinical practice requires extensive research, clinical trials, and collaboration among researchers and healthcare professionals.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.